medRxiv Oncology· Baraibar, I., Morabito, S., Deuner-Cos, G., Caratu, G., Melero, J. L., Berasategi, M., Soto, M., Grzelak, M., Nieto, P., Maspero, D., Salva, F., Saoudi, N., Ros, J., Perez-Lopez, R., Gros, A., Villacampa, G., Roson, N., Carmona, J., Garcia, A., Lambert, A., Martinez-Martin, N., Casbas-Hernandez, P., Zeron-Medina, J., Tabernero, J., Rotem, A., Nieto, J. C., Elez, E., Heyn, H. ·· 23 hours agoScore67
Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer
In brief
The phase II SERPENTINE trial shows that after dual PD-L1 and CTLA-4 blockade in patients with pMMR/MSS metastatic colorectal cancer, those without liver metastases had clinical benefit, while all patients with liver metastases progressed.
Source: medRxiv Oncology · medrxiv.org